ABSTRACT Introduction/Aims Durable medical equipment (DME)—wheelchairs, non‐invasive ventilation, gastrostomy tubes, and communication devices—provides vital support for individuals with amyotrophic lateral sclerosis (ALS). Here, we describe DME use in COURAGE‐ALS evaluating reldesemtiv's efficacy and safety in ALS, to evaluate if DME use can be considered an endpoint of interest in ALS trials. Methods COURAGE‐ALS, a multicentre, double‐blind, randomized, placebo‐controlled clinical trial was conducted at 83 sites in the United States, Canada, Europe, and Australia. Participants were randomized 2:1 to receive reldesemtiv or placebo for 24 weeks, followed by 24 weeks of active drug treatment. Exploratory outcomes included reasons for prescribing, extent of use, DME types, and regional differences. Results Among 482 participants, 166 (34.4%) were using at least one DME item at baseline. Among 276 participants completing study visits through Week 24, 130 (47.1%) initiated use of a total of 188 new DME items post‐baseline through 24 weeks. Manual wheelchairs were most used at baseline (89 items) and initiated (47 items) during the trial. Both baseline DME use and initiating a new item were associated with lower ALS Functional Rating Scale‐Revised scores and worse quality of life. The trial was terminated early due to futility. Treatment assignment did not impact DME use. Regional disparities were noted. Discussion This study shows that DME is commonly prescribed to ALS trial participants. Further understanding of geographic differences in DME access and their impact on clinical outcomes is warranted prior to including DME use as an endpoint in ALS trials. Trial Registration: ClinicalTrials.gov identifier: (NCT04944784)
Rudnicki et al. (Mon,) studied this question.